DRI Healthcare Trust Overview
Pro stress-test →DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties, owning a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focus on eight therapeutic areas. The company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies.
Strategic Profile
Pro stress-test →The company provides differentiated exposure to the fast-growing pharmaceutical and biotechnology industries through ownership and acquisition of royalties on pharmaceutical products, with a focus on delivering attractive growth in cash receipts from royalty assets over the long term. DRI Healthcare Trust is a global leader in providing financing to advance innovation in the life sciences industry.
Competitive Landscape
Pro stress-test →DRI Healthcare Trust operates in the pharmaceutical royalty monetization sector with limited direct competitors. The company competes primarily with other royalty income trusts and biopharma investment vehicles seeking exposure to pharmaceutical royalties. DRI's competitive advantages include its portfolio of 28 royalty streams on proven blockbuster drugs, scale of deployed capital exceeding $1 billion, and backing from DRI Capital Inc., a pioneer in pharmaceutical royalty monetization.
Industry Context
DRI Healthcare Trust operates in Pharmaceutical Royalty Monetization / Life Sciences Financing.
Key facts
Founded: 2020 · Headquarters: Toronto, Canada · Revenue: $184.7M · Market cap: $270.5M CAD